- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alkermes Plc (ALKS)
Alkermes Plc stock price live, this page displays NASDAQ ALKS stock exchange data. View the ALKS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alkermes Plc real time stock price chart below.
What Is the Alkermes Plc Stock Price Today?
The Alkermes Plc stock price today is 51.94.
What Is the Stock Symbol for Alkermes Plc?
The stock ticker symbol for Alkermes Plc is ALKS.
Is ALKS the Same as $ALKS?
$ALKS is a common way to refer to the Alkermes Plc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
Is Alkermes Plc a Good Stock to Buy?
Determining whether Alkermes Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Alkermes Plc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALKS quote. (ISIN: IE00B56GVS15)
What Is the Alkermes Plc Stock Price Today?
The Alkermes Plc stock price today is 51.94.
What Is the Stock Symbol for Alkermes Plc?
The stock ticker symbol for Alkermes Plc is ALKS.
Is ALKS the Same as $ALKS?
$ALKS is a common way to refer to the Alkermes Plc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
Is Alkermes Plc a Good Stock to Buy?
Determining whether Alkermes Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Alkermes Plc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALKS quote. (ISIN: IE00B56GVS15)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51.86
53.38
52 wk Range
25.17
55.67
ALKS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51.8653.38
52 wk Range
25.1755.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALKS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
50.56
Downside
-2.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
- Alkermes stock hits 52-week high at 55.28 USD
- Investing.com
- Alkermes Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Alkermes stock hits 52-week high at 55.28 USD
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
14 Buy
2 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 50.56
(-2.65% Downside)
Alkermes Plc SWOT Analysis
Analyst Outlook | Price targets range from $43 to $48, reflecting optimism about Alkermes' transformation into a high-growth "Neuro-Innovator" over the next 12-24 months |
Pipeline Potential | Explore ALKS 2680's game-changing potential in sleep disorders and the company's expansion into larger therapeutic areas through Project Saturn |
Financial Strength | With $1 billion in cash and strong product growth, Alkermes maintains a robust financial position despite challenges from royalty losses |
CNS Market Leade | Alkermes transitions from royalty-driven to proprietary product-focused model, positioning itself as a key player in the competitive CNS therapeutics space |
Alkermes Plc Earnings Call Summary for Q1/2026
- Alkermes Q1 2026 EPS of -$0.40 beat estimates of -$0.54 by 26%; revenue reached $392.9M vs. $362.9M expected, driving 2.43% stock gain.
- Avadel Pharmaceuticals acquisition fueled 38% YoY proprietary product sales growth to $338.1M; adjusted EBITDA hit $80.3M, exceeding $30M-$50M guidance.
- Company raised 2026 outlook: proprietary sales to exceed $1.7B, GAAP net loss narrowed to $70M-$90M, adjusted EBITDA above $370M projected.
- CEO Pops credited strategic execution and Avadel integration; LUMRYZ sleep medicine shows strong growth potential with positive market reception.
Last Updated: 05/05/2026, 09:42 AM
Read Full TranscriptAlkermes Plc investor slides for Q1/2026
Last Update: May 05, 2026
See full investor slides
Earnings
Latest Release
May 05, 2026
EPS / Forecast
-0.40 / -0.54
Revenue / Forecast
392.91M / 362.85M
Compare ALKS to Peers and Sector
Metrics to compare | ALKS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALKSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 56.7x | 12.1x | −0.4x | |
PEG Ratio | −1.00 | 0.32 | 0.00 | |
Price / Book | 4.9x | 2.7x | 2.6x | |
Price / LTM Sales | 5.5x | 2.1x | 3.0x | |
Upside (Analyst Target) | −7.6% | 26.6% | 51.5% | |
Fair Value Upside | Unlock | 20.8% | 8.8% | Unlock |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alkermes Plc (ALKS) Stock Price Today?
The Alkermes Plc stock price today is 51.94 USD.
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Alkermes Plc?
The stock symbol for Alkermes Plc is "ALKS."
What Is the Alkermes Plc Market Cap?
As of today, Alkermes Plc market cap is 8.66B USD.
What Is Alkermes Plc's Earnings Per Share (TTM)?
The Alkermes Plc EPS (TTM) is 0.91.
When Is the Next Alkermes Plc Earnings Date?
Alkermes Plc will release its next earnings report on Jul 29, 2026.
From a Technical Analysis Perspective, Is ALKS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Alkermes Plc Stock Split?
Alkermes Plc has split 1 times.
How Many Employees Does Alkermes Plc Have?
Alkermes Plc has 2050 employees.
What is the current trading status of Alkermes Plc (ALKS)?
As of Jul 13, 2026, Alkermes Plc (ALKS) is trading at a price of 51.94 USD, with a previous close of 53.78 USD. The stock has fluctuated within a day range of 51.86 USD to 53.38 USD, while its 52-week range spans from 25.17 USD to 55.67 USD.
What Is Alkermes Plc (ALKS) Price Target According to Analysts?
The average 12-month price target for Alkermes Plc is 50.56 USD, with a high estimate of 65 USD and a low estimate of 34 USD. 14 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -2.65% Downside potential.
What Is the ALKS Premarket Price?
ALKS's last pre-market stock price is 53.75 USD. The pre-market share volume is 470.00, and the stock has decreased by -0.03, or -0.06%.
What Is the ALKS After Hours Price?
ALKS's last after hours stock price is 51.00 USD, the stock has decreased by -0.94, or -1.81%.
Industry Spotlight
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.